← ANALYST RATINGS · TIPRANKS
Karyopharm Therapeutics (KPTI): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy1 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $7.25, the highest $11.00, the lowest $3.00. The average is +1,759.0% from the last price of $0.39.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.30 → $0.34+11.3% | Hold | −13.8% | Reiterated | 16.10.26on TipRanks 11:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.30 → $0.33+11.4% | Sell | −14.6% | Reiterated | 16.10.26on TipRanks 11:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.30 → $0.34+11.3% | Hold | −13.8% | Reiterated | 16.10.26on TipRanks 11:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.30 → $0.33+11.1% | Sell | −15.1% | Reiterated | 16.10.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.30 → $0.33+11.4% | Sell | −14.6% | Reiterated | 16.10.26on TipRanks 11:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.30 → $0.33+11.4% | Sell | −14.6% | Downgrade | 16.10.26on TipRanks 11:05 | — | |
| Yanni Souroutzidis★★★★★★★★★★#10612 · hits 25% · avg −16.7% | Cantor Fitzgerald | $3.68 | Buy | +843.6% | Reiterated | 01.09.26on TipRanks 08:50 | −9.5%next day −3.7% · 5 days −8.7% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $8.00 | Buy | +1,951.3% | Reiterated | 13.08.26on TipRanks Aug 17 21:45 | −2.7%next day +1.7% · 5 days −6.6% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $14.00 → $11.00−21.4% | Buy | +2,720.5% | Reiterated | 31.07.26on TipRanks 10:46 | −73.3%next day +1.2% · 5 days +6.9% | ↗ |
| Colleen M. Kusy★★★★★★★★★★#12105 · hits 35% · avg −6.9% | Robert W. Baird | — | Hold | — | Downgrade | 31.07.26on TipRanks 07:51 | −73.3%next day +1.2% · 5 days +6.9% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $16.00 → $7.00−56.2% | Buy | +1,694.9% | Reiterated | 31.07.26on TipRanks 07:27 | −73.3%next day +1.2% · 5 days +6.9% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $13.00 → $3.00−76.9% | Hold | +669.2% | Downgrade | 31.07.26on TipRanks 06:38 | −73.3%next day +1.2% · 5 days +6.9% | ↗ |
| Unknown Analyst | Leerink Partners | $5.00 → $7.00+40.0% | Hold | +1,694.9% | Reiterated | 15.05.26on TipRanks May 16 10:05 | −12.6%next day −6.8% · 5 days +5.5% | ↗ |
| Michael King★★★★★★★★★★#11053 · hits 39% · avg −2.3% | Rodman & Renshaw | $28.00 | Buy | +7,079.5% | Initiated | 09.03.26on TipRanks 16:25 | −2.9%next day +6.4% · 5 days +2.8% | ↗ |
| Peter Lawson★★★★★★★★★★#602 · hits 47% · avg +15.5% | Barclays | $10.00 | Buy | +2,464.1% | Reiterated | 04.11.25on TipRanks 03:20 | −5.7%next day −5.5% · 5 days −4.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Karyopharm Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.54 at a price of $1.22 (+435.7%); now: $6.54 at $0.39 (+1,575.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 3 | 5 | 5 | 5 | 1 |
| Buy | 1 | 2 | 3 | 2 | 1 | 0 |
| Hold | 0 | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.95 (from $-1.37 to $-0.34). Last quarter: $-2.32.
Sales
Next quarter’s sales estimate — $34M (from $32M to $35M). Last quarter: $33M.
Best top-analyst consensus in the sector · Healthcare
About Karyopharm Therapeutics
- CEO: Richard A. Paulson
- Employees: 228
- 85 Wells Avenue, Newton, MA, 02459-3298, US
- www.karyopharm.com
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Data from the stock’s TipRanks forecast page, read 78 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗